• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Waters and Genovis Enter Biopharmaceutical Partnership

    Frontage Acquires Ocean Ridge Biosciences

    AGC Biologics Expands Partnership with Rocket Pharmaceuticals

    TraceLink Introduces Opus Platform

    Evotec to Build Second Biologics Mfg. Facility in Toulouse
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Evotec to Build Second Biologics Mfg. Facility in Toulouse

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    TraceLink Introduces Opus Platform

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Decentralized Clinical Trials: The 101 on Digital Health Technologies (DHTs)

    Lessons Learned: Choosing and Managing a CDMO

    Waters and Genovis Enter Biopharmaceutical Partnership

    AGC Biologics Expands Partnership with Rocket Pharmaceuticals

    TraceLink Introduces Opus Platform
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Adare Pharma Solutions

    Quotient Sciences

    Aphena Pharma Solutions

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Quotient Sciences

    PCI Pharma Services

    Reed-Lane

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Consolidation in Outsourcing

    Reviewing 2014’s M&A activity

    Related CONTENT
    • Kintor, Visum Enter COVID-19 Manufacturing Partnership
    • Catalent Adds Cryogenic Capabilities at Philadelphia Facility
    • Thermo Fisher Scientific to Acquire PPD
    • Thermo Fisher Acquires PPD for $17.4B
    • Metrics Names Stephanie Emory Associate Director of Pharma Development
    Michael A. Martorelli , Director, Fairmount Partners03.06.15
    In our review of 2013 M&A activity (Contract Pharma January/February 2014), we suggested the need to examine the why of making acquisitions before considering the details of who, when, where, and how much. Let us briefly refer the reader to the opening paragraphs of that article in noting that the two largest transactions in 2014 seemed to defy the conventional wisdom regarding the why question. Neither would have been on our short list of predicted acquisitions to be expected in the broad outsourcing arena.

    First, the diversified drug company Merck KGaA agreed to pay approximately $17 billion in cash to acquire the manufacturing and distribution company Sigma-Aldrich. Then the laboratory services provider Laboratory Corporation of America agreed to purchase the diversified contract services firm Covance Inc. for $6.1 billion.

    Frankly, we’re leaving it to others to address the buyers’ rationales in taking these bold steps to help them achieve one or more of their long-term strategic objectives. Instead, we’ll focus our annual examination of the consolidations announced or completed last year on answering the traditional questions of who, when, where, and sometimes how much.

    It’s always interesting to review the number of consolidating transactions described in any particular 12-month period. In calendar 2014, our count was only 145, compared to 140 and 170 in the previous two years. But we’ll repeat our often-stated opinion that the raw number of deals announced or closed in any time period masks the reality of a continually high level of interest in M&A activity among a range of potential buyers and sellers in the global outsourcing industry’s many sectors.

    Rather than commenting on all the announced deals, we’ll use the following pages to highlight certain transactions we believe were representative of larger trends.

    The Largest Firms Were Quite Active
    During the past year, we read several articles in industry newsletters and other investment banking firms’ digests suggesting a dramatic slowdown in the M&A activities of the largest outsourcing firms. We acknowledge the reduced number of acquisitions made by some industry leaders, but dispute the notion that those firms are no longer interested in pursuing this avenue of growth. Several multi-billion dollar companies used that route to expand their businesses in additional specialty categories.

    Catalent Inc. followed its successful July initial public offering (IPO) with the acquisition of two companies with specialized capabilities: Redwood Biosciences with its SMARTag Antibody-Drug Conjugate (ADC) technology platform, and Micron Technologies, a provider of particle size engineering technologies.

    Charles River Laboratories was particularly active in acquiring additional specialty technologies—a broad trend we note later in this article. It acquired the Argenta and BioFocus divisions of Galapagos NV, thus adding their in vitro discovery services to its traditional complement of in vivo capabilities. The company also acquired ChanTest, the world leader in ion channel testing for safety and drug discovery.

    Covance Inc. acquired London-based Medaxial, a company providing a range of services involving market access, health economic modeling, and competitive assessment. Like most large CROs, Covance recognizes the need to help its clients not only develop new drugs but also make them successful commercial products.

    ICON plc made one of the largest acquisitions in the industry when it paid $144 million in cash to purchase Aptiv Solutions. Analysts expect the acquisition to help ICON further penetrate the Phase III market for adaptive clinical trials.

    INC Research expanded its presence in the Middle East and North Africa with the purchase of MEK Consulting and its 40 employees based in those regions.

    PPD Inc. is another large firm that has been expanding its technology portfolio. In September, it acquired from Massachusetts General Hospital the exclusive license to a portfolio of patents related to an alternate method of decreasing the impact of the placebo effect in clinical trials. That same month, it also exercised its option to buy the remaining minority interest in X-Chem Inc. and that firm’s proprietary small molecule drug discovery engine.

    PAREXEL International made two complementary purchases that management suggested would add modestly to revenue and earnings in the current fiscal year. In July, it acquired ATLAS Medical Services, a provider of clinical research services in Turkey, the Middle East, and Africa. In October, it acquired Clinintel, a provider of clinical randomization and trial supply management services based in the United Kingdom.

    Quintiles Inc. continued to build the portfolio of its Integrated Healthcare Services segment with the July purchase of Encore Health Resources. That firm provides health-information analytics and electronic hearth record services to large hospital systems and academic medical centers.

    Several sector-leading firms with annual revenue ranging from $100 million to $1.0 billion made a few acquisitions that would seem to be more meaningful than those made by their larger competitors.

    If the transactions announced in early January 2015 are completed, AMRI will have spent more than $210 million to acquire four separate businesses during the past twelve months. In April, it paid $41 million to acquire Cedarburg Pharmaceuticals, a contract manufacturer of technically complex APIs. In July, it paid another $110 million in cash to acquire Oso Biopharmaceuticals Manufacturing, a contract manufacturer of complex injectable drug products. And in early January, it agreed to pay Aptuit $60 million for product development/manufacturing facilities in Glasgow, Scotland and West Lafayette, Indiana. Thus, it appears to analysts that AMRI has expanded its potential 2015 revenue base to close to $340 million.

    In March, the private equity firms controlling BioClinica, Inc. and CCBR-SYNARC agreed to combine those companies into a firm generating approximately $200 million in revenue from a portfolio of specialized outsourcing services. In June, the company acquired Blueprint Clinical, thus adding a cloud-based site-scoring tool to its capabilities in medical imaging, patient recruitment, and central lab services.

    After a new group of investors recapitalized Chiltern in late 2013, management boosted the company’s annualized revenue rate to more than $200 million. Major contributions were made by the acquisitions of the oncology specialist Ockham Development Group in July and the pan-Asian CRO Pacific Clinical Research Pte. in September.

    In May, the Huntingdon, UK-based Huntingdon Life Sciences acquired the Indianapolis, IN-based competitor Harlan Life Sciences. The combined company generates annualized revenue of approximately $500 million, largely by providing preclinical research services.

    After going public in April, the Swedish contract manufacturer Recipharm AB spent the next six months increasing its annualized revenue base by more than 50% to more than $500 million. It did so by acquiring Corvette Pharmaceutical Services Group in Milan Italy, Lusomedicamenta Sociedade Tecnica Farmaceutica in Lisbon, Portugal, and the Flamel Technologies development and manufacturing facility in Pessac, France.

    In October, the China-based laboratory and manufacturing services company WuXi PharmaTech expanded its annualized revenue base towards the $670 million level with the acquisition of the specialized DMPK and ADME provider XenoBiotic Laboratories. And in January 2015, WuXi entered the genomic analysis business by paying $65 million in cash to acquire NextCODE Health.

    Private Equity Groups Made Many New Investments
    Once again, private equity (PE) funds with existing positions in outsourcing and those making their first investment in that arena were active buyers.

    Arsenal Capital Partners bought Certara from Vector Capital; the London-based European firm Cinven bought Medpace from CCMP Capital Advisers; Golden Gate Capital bought 75% of Phillips-Medisize, a contract manufacturer to many industries, including pharmaceuticals; Great Point Partners invested in Cytovance Biosciences; Main Market Partners acquired Ricerca Biosciences; Newspring Capital and Camden Partners invested in Paragon Bioservices; and Warburg Pincus invested in Laurus Labs.

    And They Supported Their Existing Portfolio Companies Growth Plans
    As usual, we tracked several acquisitions by companies owned or controlled by PE groups. The source of the funding for these acquisitions may or may not have included additional dollars invested by their PE partners. We’ve already noted acquisitions made by BioClinica and Chiltern.

    Clinipace Worldwide, controlled by Hatteras Venture Partners, bought Choice Pharma; DrugDev, controlled by Invesco Perpetual, bought Trial Networks; eResearch Technology, controlled by Genstar Capital, bought eClinical Insights; Packaging Coordinators Inc., controlled by Frazier Healthcare, bought Penn Pharmaceutical Services.

    But They Also Liquidated A Few Holdings
    One of the big stories of 2014 was the high number of IPOs completed by outsourcing service providers. Most of them involved the partial liquidation of long-held ownership positions by one or more PE firms.

    Avista Capital Partners sold part of its holdings in INC Research; Blackstone sold part of its holdings in Catalent Inc.; Bain Capital sold a portion of its holdings in IMCD Group; Along with TPG Capital, Temasek Holdings, and 3iGroup, Bain also sold additional shares in Quintiles; and TPG Capital, along with Leonard Green & Partners, also sold part of its holdings in IMS Health. These firms, as well as the PE owners that did not sell any shares in the IPOs of PFEnex, PRA Health Sciences and Recipharm AB, remain meaningful holders of the aforementioned companies.

    Many Firms Expanded Their Specialty Technology Capabilities
    Throughout 2014, we noted a high degree of activity involving the acquisition of specialty technologies used in laboratory analysis, drug formulation, and various types of preclinical or clinical testing. Even pure-play service providers have been seeking to differentiate themselves from competitors by expanding these capabilities. Earlier, we highlighted technology acquisitions made by Catalent, Charles River Laboratories, PPD Inc., and WuXi Pharma Tech. Several other transactions also caught our eye.

    Advanced Bioscience Laboratories acquired a majority interest in Platine Pharma Services. The Lyon, France-based Platine provides a variety of technology-enabled immunological testing services to customers in the biopharmaceutical, food, cosmetic and diagnostic industries.

    Evotec AG acquired the Manchester, UK-based Europrotec Ltd., a provider of assays and disease models used to discover drugs for treating infectious diseases. Thus, Evotec added this new disease franchise to its existing discovery platforms, and enhanced the opportunities in its nascent TargetX programs.

    GVK BIO acquired Aragen Bioscience, Inc. a preclinical CRO specializing in high-value biological services for large molecules. This was Hyderabad-based GVK’s first international acquisition; Aragen is headquartered in Morgan Hill, CA.

    Horizon Discovery Group acquired the CombinatoRX service business and assets from Zalicus. This new division gave Horizon access to the unique cHTS platform and Chalice analytics software, which enable the screening and analysis of thousands of complementary drug combinations.

    Miltenyi Biotec acquired the lentiviral vector manufacturing business of Lentigen, thus adding the ability to deliver genetic material into cells to its existing range of cGMP manufacturing capabilities.

    Consolidation Continued in the IRB Sector
    Many trade publications have traced the consolidation that’s occurred among the U.S.’s Institutional Review Boards (IRBs) during the past couple of years. The first shots in that war to gather many of those individual review and monitoring organizations into only a few multi-panel operators occurred in 2012 when Arsenal Capital Partners acquired both WIRB and Copernicus Group.

    Last year, WIRB-Copernicus acquired three other IRBs: Aspire, Midlands, and New England. It also acquired the biosafety consulting firm Alliance Bioscience and the clinical trials portal developer ePharmaSolutions.

    Two other private equity firms also made investments in this sector: Chesapeake IRB, controlled by Audax Group, acquired Goodwyn IRB and IRB Services; and American Capital Equity invested in Schulman Associates IRB.

    There Were Other Intriguing Combinations
    Every year, there seem to be several companies that seek to expand the scope of their operations through targeted acquisitions of smaller or similarly sized firms. We comment briefly on just a few of such transactions that particularly intrigued us in 2014.

    The Warsaw-based European CRO KCR acquired 15 clinical projects and almost the entire clinical operations team from the Ukranian CRO Axis Group.

    MPI Research acquired Jasper Clinical Research & Development. Thus, this leading provider of preclinical animal studies and drug safety evaluation services established a presence in early stage human clinical testing.

    Nashville, TN-based Sarah Cannon Research Institute added to its network of more than 700 community-based oncologists in 25 states with the acquisition of Clinical Development Group, a clinical trial consulting firm in New Haven, CT.

    Early stage CRO Simbec Research acquired the late stage CRO Orion Clinical Services Limited. The merger of these two UK-based companies resulted in one with 250 employees and an annualized revenue base of about £25 million.

    Chinese CRO Tigermed acquired a majority stake in Frontage Laboratories, a provider of bioanalytical and discovery support services in the United States and China.

    London-based CRO Venn Life Sciences acquired CROs in Germany (CRM Clinical Trials), Northern Ireland (Medevol Limited), and France (Cardinal Systems). It also acquired the rights to LabSkin, a human skin substitute and SYN113 (an anti-acne compound) from the dermatology CRO Evocutis.

    What Type of Activity do we Expect in 2015?
    Simply put, we expect more of the same. The largest firms will continue to seek selective opportunities in specific service categories while the still-expanding mid-sized firms will continue to seek ways to serve more clients. At the same time smaller firms will continue to sell to strategic and financial partners and private equity firms will continue to be active as both buyers and sellers.
    Whether they like it or not, all participants must face the fact: consolidation is a permanent feature of the pharmaceutical outsourcing industry. 


    Michael A. Martorelli is a Director at the investment banking firm Fairmount Partners. For additional commentary on the topics covered in this article, contact him at michael.martorelli@fairmountpartners.com or by phone at (610) 260-6232; fax (610) 260-6285.
    Related Searches
    • catalent
    • cGMP
    • Bioanalytical
    • Pharma
    Suggested For You
    Kintor, Visum Enter COVID-19 Manufacturing Partnership Kintor, Visum Enter COVID-19 Manufacturing Partnership
    Catalent Adds Cryogenic Capabilities at Philadelphia Facility Catalent Adds Cryogenic Capabilities at Philadelphia Facility
    Thermo Fisher Scientific to Acquire PPD Thermo Fisher Scientific to Acquire PPD
    Thermo Fisher Acquires PPD for $17.4B Thermo Fisher Acquires PPD for $17.4B
    Metrics Names Stephanie Emory Associate Director of Pharma Development Metrics Names Stephanie Emory Associate Director of Pharma Development
    BioVersys Gets EIB Funds to Address Antimicrobial Resistance BioVersys Gets EIB Funds to Address Antimicrobial Resistance
    Catalent Biologics Completes Madison Expansion Catalent Biologics Completes Madison Expansion
    Woodstock Sterile Solutions Appoints CCO Woodstock Sterile Solutions Appoints CCO
    Vetter Development Service Vetter Development Service
    Vetter Commercial Manufacturing Vetter Commercial Manufacturing
    AJILITY: Intelligent Drug Product Manufacturing AJILITY: Intelligent Drug Product Manufacturing
    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans Agilex Biolabs Acquires TetraQ for APAC Expansion Plans
    Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment
    Moleculin Selects IQVIA Biotech to Advance COVID Treatment Moleculin Selects IQVIA Biotech to Advance COVID Treatment
    Cryoport Acquires Critical Transport Solutions Australia Cryoport Acquires Critical Transport Solutions Australia

    Related Features

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20

    • Drug Development | Drug Discovery | R&D
      R&D Outsourcing Trends

      R&D Outsourcing Trends

      Highly specialized drug products and capacity needs drive increased reliance on contract service providers.
      Kristin Brooks, Managing Editor, Contract Pharma 10.14.20


    • Drug Discovery
      Drug Discovery Technology Trends

      Drug Discovery Technology Trends

      Combining native mass spectrometry with fragment-based drug discovery in medicinal chemistry
      Sally-Ann Poulsen, Professor of Chemical Biology, Griffith Institute for Drug Discovery (GRIDD), Griffith University 09.16.19

    • Clinical Trials
      Gene Therapy Trials

      Gene Therapy Trials

      Applications and the limitations of real-world data.
      Karen Ooms, Executive Vice President and Head of Statistics, Quanticate 09.16.19

    • Clinical Trials | Information Technology
      The New Horizon: Metaprise Analytics in Life Sciences

      The New Horizon: Metaprise Analytics in Life Sciences

      Going beyond enterprise analytics to metaprise analytics—patient-centric systems that create a data driven trial team.
      Michelle Longmire, MD, CEO and Founder, Medable 05.07.19


    • Clinical Trials
      Clinical Trial Feasibility

      Clinical Trial Feasibility

      How to reduce late-stage trial risk with feasibility analysis
      Alan Scott and Denis McMillan, PAREXEL International 04.05.19

    • Clinical Trial Materials | Clinical Trials | Supply Chain
      Optimizing Clinical Supply Management

      Optimizing Clinical Supply Management

      IRT system design strategies to help life science companies cut drug wastage across clinical programs.
      Bart Nicholson, Director of Customer Success for IRT, CRF Bracket 04.05.19

    • Clinical Trials | R&D
      Improving Pharma R&D Efficiency: The need to transform clinical trials

      Improving Pharma R&D Efficiency: The need to transform clinical trials

      Cost pressures on drug development are driving the search for savings and efficiencies—but efforts need to be integrated if t
      ICON plc 10.10.18


    • Drug Discovery
      How Can We Predict Immunogenicity Earlier in Drug Discovery?

      How Can We Predict Immunogenicity Earlier in Drug Discovery?

      Identifying potential immune responses earlier in the development of biotherapeutics.
      Kevin Merlo and Tim Moran, Dassault Systèmes Biovia 09.01.17

    • Clinical Trials
      Tracking Health

      Tracking Health

      Exploring the impact of wearable health monitoring tools on CROs
      Nigel Walker 05.09.17

    • Clinical Trials | Drug Development | Preclinical Outsourcing | R&D
      CROs and Today’s  R&D Landscape

      CROs and Today’s R&D Landscape

      John Lewis of ACRO discusses opportunities, challenges, and the future CRO
      Kristin Brooks, Associate Editor, Contract Pharma 11.09.16


    • Analytical Services | Drug Development | Drug Discovery | Preclinical Outsourcing | R&D
      The Human Parts of Mouse Models

      The Human Parts of Mouse Models

      The PDX model system has come back into focus
      Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company 10.11.16

    • APIs | Clinical Trial Materials | Clinical Trials | Drug Development | Formulation Development
      Choosing Oral Formulations for First-in-man Clinical Trials

      Choosing Oral Formulations for First-in-man Clinical Trials

      Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems
      Jon Sutch, Senior Manager of Formulation Development, Patheon 10.11.16

    • Analytical Services | Bioassay Development | Clinical Trials | Preclinical Outsourcing | R&D
      Robust Assay Designs

      Robust Assay Designs

      Easing the transition from preclinical to clinical research
      Tim Wright, Editor, Contract Pharma 10.11.16

    Trending
    • Pfizer, BioNTech Expand COVID-19 Vaccine Agreement With EU
    • Obituary Notice: Russell “Russ” Haines
    • Resilience Acquires Ology Bioservices
    • Johnson & Johnson 1Q Results
    • Sartorius Expands In The UK
    Breaking News
    • Waters and Genovis Enter Biopharmaceutical Partnership
    • Frontage Acquires Ocean Ridge Biosciences
    • AGC Biologics Expands Partnership with Rocket Pharmaceuticals
    • TraceLink Introduces Opus Platform
    • Evotec to Build Second Biologics Mfg. Facility in Toulouse
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Innova Market Insights: Sports Nutrition Must Focus on Flavors for Mainstream Consumers
    Probiotic Strain Evidenced to Reduce Iron Deficiency/Anemia Risk
    Longvida Curcumin Extract Receives ANVISA Approval in Brazil
    Coatings World

    Latest Breaking News From Coatings World

    Keim-additec Hires Tyler John as Technical Sales Manager
    Nouryon Appoints Julie Aslaksen to Board of Directors
    RadTech Announces New Board Members, Secretary, Honorary Lifetime Member
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    J&J’s Veritas Vision System Receives FDA Clearance and CE Mark
    Viz.ai’s AI-Powered Platform Can Improve Outcomes for Stroke Patients
    FDA Breakthrough Device Designation Granted for pdSTIM System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Waters and Genovis Enter Biopharmaceutical Partnership
    Frontage Acquires Ocean Ridge Biosciences
    AGC Biologics Expands Partnership with Rocket Pharmaceuticals
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    How Do Americans Feel About Diversity in Beauty Advertising?
    Estée Lauder Companies Reaffirms Sustainability Goals for Earth Month
    Coty’s Lancaster Earns C2C Certified Material Health Certificate
    Happi

    Latest Breaking News From Happi

    FDA Cites Disinfection Issues at Proposed Vaccine Production Site
    It's Official! L'Oréal Gets New CEO on May 1
    New Beauty Brand sk*p Wants to Break Addiction to Plastic
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Global Graphics unveils new SmartDFE
    Channeled Resources installs new slitter in Toronto facility
    Kao Collins launches new website for printing inks and services
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FiberVisions, Avgol Partner with Polymateria
    High-Tech Conversation Launches Wipes Dispenser
    Because Market Debuts Premium Plus Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Patients Conclude Clinical Visits in Knee Osteoarthritis Treatment Study
    SeaSpine Begins Limited Rollout of WaveForm TO 3D-Printed Interbodies
    Spinal Elements' Lucent 3D Additive Manufactured Interbodies Earn FDA Nod
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    SEMI Appoints imec, Soitec Executives to Europe Advisory Board
    TechBlick Announces Agenda For Next Printed, Hybrid, Structural, 3D Electronics Virtual Event
    NREL Takes Novel Approach to 3D-Printed Water Power Prototypes

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login